Getinge Group: Reporting Period January – March

  Getinge Group: Reporting Period January – March

Business Wire

GETINGE, Sweden -- April 17, 2013

Regulatory News:

· Order intake rose by 3.0% to SEK 5,968 M (5,795), and grew organically by
1.8%

· Net sales increased by 8.0% to SEK 5,664 M (5,246), and grew organically by
6.6%

· Profit before tax declined by 55.8% to SEK 252 M (570). Profit was charged
with SEK 240 M (0) in restructuring costs.

· Earnings per share decreased by 56.8% to SEK 0.76 (1.76)

· EBITA before restructuring declined by 7.3% to SEK 792 M (854). Adjusted for
currency effects and the Medical Device Tax introduced in the US, EBITA rose
by 8%

First quarter 2013

While demand for the Group’s medical-technical capital goods continues to
experience a challenge in the Western European market, which has yet to hit
bottom, volume expectations in the markets outside Western Europe improved
during the quarter. Work on strengthening the Group’s competitiveness and
profitability continue, and a number of efficiency enhancement projects were
initiated during the quarter.

Orders received

The Group’s order intake increased organically by 1.8% during the quarter. For
the Group’s largest business area, Medical Systems, order intake grew
organically by a highly favourable 7.5%, with strong growth in the
Cardiovascular and Critical Care division. For Extended Care, which has
considerable exposure to the elderly care sector and the more mature Western
European and North American markets, order intake declined organically by
4.2%. In Infection Control, order intake declined organically by 4.6%. While a
weaker Life Science market resulted in a volume decline for Infection Control,
demand from hospital customers experienced a strong trend.

Demand in the Western European markets remains challenging and difficult to
assess, particularly in terms of the southern European markets. The North
American market has stabilized and all business areas reported a positive
volume trend in the US during the quarter. The demand scenario remains robust
in the markets outside Western Europe and North America.

Teleconference with CEO Johan Malmquist and CFO Ulf Grunander 17 April 2013 at
3:00 p.m. Swedish time

Swedish dial in number: +46 8 5853 6965

UK dial in number: +44 20 3478 5300

US dial in number: +1212444 0412

Participant passcode: 224195

GETINGE GROUP (STO:GETIB) is a leading global provider of products and systems
that contribute to quality enhancement and cost efficiency within healthcare
and life sciences. We operate under the three brands of ArjoHuntleigh, GETINGE
and MAQUET. ArjoHuntleigh focuses on patient mobility and wound management
solutions. GETINGE provides solutions for infection control within healthcare
and contamination prevention within life sciences. MAQUET specializes in
solutions, therapies and products for surgical interventions, interventional
cardiology and intensive care.

The information is such that Getinge AB must disclose in accordance with the
Swedish Securities Market Act and/or the Financial Instruments Trading Act.

This information was brought to you by Cision http://news.cision.com

Contact:

Communications
Phone: +46 (0)10 335 5810